- Home
- WAFU vs RNAZ Comparison
WAFU vs RNAZ Comparison
Compare WAFU & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAFU
- RNAZ
- Stock Information
- Founded
- WAFU 1999
- RNAZ 2016
- Country
- WAFU China
- RNAZ United States
- Employees
- WAFU N/A
- RNAZ N/A
- Industry
- WAFU Other Consumer Services
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- WAFU Real Estate
- RNAZ Health Care
- Exchange
- WAFU Nasdaq
- RNAZ Nasdaq
- Market Cap
- WAFU 7.1M
- RNAZ 7.2M
- IPO Year
- WAFU 2019
- RNAZ 2021
- Fundamental
- Price
- WAFU $1.83
- RNAZ $8.08
- Analyst Decision
- WAFU
- RNAZ Strong Buy
- Analyst Count
- WAFU 0
- RNAZ 1
- Target Price
- WAFU N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- WAFU 46.3K
- RNAZ 4.3M
- Earning Date
- WAFU 01-01-0001
- RNAZ 03-31-2025
- Dividend Yield
- WAFU N/A
- RNAZ N/A
- EPS Growth
- WAFU N/A
- RNAZ N/A
- EPS
- WAFU N/A
- RNAZ N/A
- Revenue
- WAFU $7,223,220.00
- RNAZ N/A
- Revenue This Year
- WAFU N/A
- RNAZ N/A
- Revenue Next Year
- WAFU N/A
- RNAZ N/A
- P/E Ratio
- WAFU N/A
- RNAZ N/A
- Revenue Growth
- WAFU N/A
- RNAZ N/A
- 52 Week Low
- WAFU $1.46
- RNAZ $2.66
- 52 Week High
- WAFU $2.63
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- WAFU 56.26
- RNAZ 48.31
- Support Level
- WAFU $1.63
- RNAZ $10.02
- Resistance Level
- WAFU $1.81
- RNAZ $11.30
- Average True Range (ATR)
- WAFU 0.12
- RNAZ 1.97
- MACD
- WAFU 0.00
- RNAZ -0.18
- Stochastic Oscillator
- WAFU 55.58
- RNAZ 26.75
About WAFU Wah Fu Education Group Limited
Wah Fu Education Group Ltd is involved in providing online exam preparation services and related technology solutions and also produces online training course materials in China. It develops online educational materials that are offered through the cloud and that can be used for a wide range of purposes, such as standard examination preparation, professional training, and interactive programs for educational purposes other than exam preparation. Its segments are Online Education Services, and Technological Development and Operation Service. The company generates maximum revenue from the Online Education Services segment.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.